XML 75 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814
Intangible Assets (Tables)
 12 Months Ended
Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Components of Intangible Assets
Intangible assets at September 30 consisted of:
 
2015
 
2014
(Millions of dollars)
Gross
Carrying
Amount
 
Accumulated
Amortization
 
Gross
Carrying
Amount
 
Accumulated
Amortization
Amortized intangible assets
 
 
 
 
 
 
 
Customer relationships
$
3,370

 
$
120

 
$
10

 
$
2

Developed technology
3,487

 
510

 
893

 
379

Product rights
128

 
35

 
148

 
31

Trademarks
405

 
26

 
27

 
19

Patents and other
333

 
212

 
232

 
163

Amortized intangible assets
$
7,723

 
$
903

 
$
1,308

 
$
594

 
 
 
 
 
 
 
 
Unamortized intangible assets
 
 
 
 
 
 
 
Acquired in-process research and development
$
203

 
 
 
$
44

 
 
Trademarks
2

 
 
 
2

 
 
Unamortized intangible assets
$
205

 
 
 
$
46

 
 
Reconciliation of Goodwill by Business Segment
The following is a reconciliation of goodwill by business segment:
(Millions of dollars)
Medical
 
 
Life Sciences
 
 
Total
Goodwill as of September 30, 2013
$
511

 
 
$
598

 
 
$
1,109

Acquisitions
—

 
 
13

(A)
 
13

Currency translation/other (B)
(29
)
 
 
(3
)
 
 
(32
)
Goodwill as of September 30, 2014
$
482

 
 
$
608

 
 
$
1,090

Acquisitions
6,585

(C)
 
130

(D)
 
6,716

Currency translation/other (B)
(261
)
 
 
(8
)
 
 
(269
)
Goodwill as of September 30, 2015
$
6,807

 
 
$
730

 
 
$
7,537

(A)
Represents goodwill recognized upon the Company’s acquisition of Alverix in the second quarter of fiscal year 2014.
(B)
Includes amounts resulting from foreign currency translation as well as acquisition accounting adjustments.
(C)
Primarily represents goodwill recognized upon the Company’s acquisition of CareFusion in the second quarter of fiscal year 2015. Additional disclosures regarding the CareFusion acquisition are provided in Note 9. Also includes $22 million of goodwill associated with individually immaterial acquisitions, including the CRISI and ARX acquisitions in the second and third quarters of fiscal year 2015, respectively.
(D)
Represents goodwill recognized upon the Company’s acquisitions of GenCell and Cellular Research in the first and fourth quarters of fiscal year 2015, respectively.